CLE-100

DRUG2 trials

Sponsors

Clexio Biosciences Ltd.

Conditions

Adjunctive Treatment of Major Depressive DisorderAdjunctive Treatment of Major Depressive Disorder (MDD)

Phase 2

A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study

CompletedNCT04103892

Clexio Biosciences Ltd.Adjunctive Treatment of Major Depressive Disorder

Start: 2019-09-05End: 2022-10-05Updated: 2025-10-14

A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder

CompletedNCT06340958

Clexio Biosciences Ltd.Adjunctive Treatment of Major Depressive Disorder (MDD)

Start: 2024-03-18End: 2025-11-25Updated: 2026-06-23